Fenfluramine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted fenfluramine, while NYE METODER (Norway) did not recommend it.
Assessment has run over 5.5 years, from 2 Dec 2020 at AWMSG (Wales) to 4 Jun 2026 at HIRA (South Korea).
AOTMIT (Poland) changed its position: not recommended on 14 Dec 2022, restricted by 22 Jul 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 18 of 26 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for fenfluramine by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 26 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess fenfluramine, on 2 Dec 2020; HIRA (South Korea) did not open a file until 4 Jun 2026 — a wide spread of 5.5 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
11 of the 14 agencies here assessed fenfluramine more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
fenfluramine has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for fenfluramine reads 12 recommended, 6 not recommended, 5 restricted and 2 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 30 Oct 2025 | Behandling af epileptiske anfald forbundet med Lennox-Gastaut syndrom som tillægsterapi til andre antiepileptiske lægemi… | Ikke anbefalet | source |
| PBAC (Australia) | 2025 | Lennox-Gastaut Syndrome (LGS) | Recommended | source |
| TLV (Sweden) | 29 Apr 2025 | Fintepla ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av epileptiske anfall forbundet med Lennox-Gastauts syndrom som tilleggsbehandling til andre antiepileptika h… | not introduced | source |
| NICE (England) | 26 Mar 2025 | NICE TA1050 | recommended (optimised) | source |
21 further decisions for fenfluramine, across 13 agencies, are not shown here. They include the most recent record on file, 4 Jun 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 18 further source documents.
Related molecules
- gadopiclenol — also decided by HIRA in 2026Q2
- atezolizumab — also decided by HIRA in 2026Q2
- avacopan — also decided by HIRA in 2026Q2
- tenecteplase — also decided by HIRA in 2026Q2
- polatuzumab vedotin — also decided by HIRA in 2026Q2
- vibegron — also decided by HIRA in 2026Q2
Coverage: 26 decisions for fenfluramine from 14 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class N03 — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.